 BLACKSBURG, Va., Oct. 06, 2021 GLOBE NEWSWIRE -- Landos Biopharma, Inc. NASDAQ: LABP, a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis in Scientific Reports. The peer-reviewed publication demonstrates omilancors therapeutic efficacy in animal models of psoriasis. 